% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lanzafame:303112,
      author       = {H. Lanzafame$^*$ and C. E. Heilig$^*$ and E. Wardelmann and
                      M. Desaulniers$^*$ and K. M. Pabst$^*$ and I. A.
                      Mavroeidi$^*$ and I. Pretzell$^*$ and P. Fragoso Costa$^*$
                      and M. Nader$^*$ and S. Leyser$^*$ and M. Schuler$^*$ and S.
                      Bauer$^*$ and J. T. Siveke$^*$ and L. Kamkar$^*$ and S.
                      Kreutzfeldt$^*$ and S. Fröhling$^*$ and S. Mühl and K.
                      Herrmann$^*$ and W. P. Fendler$^*$ and R. Hamacher$^*$},
      title        = {90{Y}-{FAPI}-46 {T}heranostics {L}eads to {N}ear-{C}omplete
                      {M}etabolic {R}esponse in 3 {P}atients with {S}olitary
                      {F}ibrous {T}umors.},
      journal      = {Journal of nuclear medicine},
      volume       = {66},
      number       = {9},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2025-01531},
      pages        = {1378-1384},
      year         = {2025},
      note         = {2025 Sep 2;66(9):1378-1384},
      abstract     = {Solitary fibrous tumor (SFT) is a rare soft-tissue sarcoma
                      with limited treatment options, especially in advanced or
                      metastatic cases. Fibroblast activation protein α (FAPα)
                      is overexpressed in certain sarcomas, including SFTs, making
                      it a promising target for diagnostics and
                      radiopharmaceutical therapy (RPT). We present the cases of 3
                      patients with metastatic SFTs who, after exhausting standard
                      treatments, underwent molecular profiling and showed
                      elevated FAPα expression. Methods: Messenger RNA and
                      protein expression of FAPα were examined in biopsy samples
                      from 3 patients participating in the Molecularly Aided
                      Stratification for Tumor Eradication Research program, a
                      multicenter observational study focused on biology-driven
                      stratification of adults with advanced cancer. Messenger RNA
                      expression levels were quantified as transcripts per
                      million, with RNA extraction, sequencing, and data
                      processing performed using established protocols. Protein
                      expression was assessed and stained with FAPα
                      immunohistochemistry using a recombinant anti-FAPα
                      antibody. Following the recommendation of the molecular
                      tumor board, these patients received 90Y-labeled fibroblast
                      activation protein inhibitor (FAPI)-46 RPT because of the
                      high uptake observed in 68Ga-FAPI-46 PET/CT scans. Results:
                      90Y-FAPI-46 RPT led to substantial clinical benefits,
                      including metabolic resolution and symptom relief, with
                      disease control confirmed using RECIST and PERCIST.
                      Treatment was well-tolerated, with only minor adverse events
                      observed. Conclusion: Our findings underscore the utility of
                      FAPα screening as a predictive biomarker and the potential
                      of FAP-targeted RPT as a viable treatment for advanced SFT.},
      keywords     = {90Y-FAPI radiopharmaceutical therapy (Other) / SFT (Other)
                      / immunohistochemistry (Other) / mRNA (Other) / sarcoma
                      (Other)},
      cin          = {ED01 / B340 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)B340-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40707141},
      doi          = {10.2967/jnumed.125.269572},
      url          = {https://inrepo02.dkfz.de/record/303112},
}